Mahesh Ramaseshan

This inventor holds 11 USPTO granted patents and 1 published patent application, plus 3 CIPO patents and 6 EPO patents. Top assignees: Tranzyme Pharma Inc., Telomerase Activation Sciences, Inc., Geron Corporation. Active years: 2008-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mahesh Ramaseshan. Retrieved from https://idiyas.com/inventor/mahesh-ramaseshan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 1)

% Patents Active = 72.7

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 5)

Average Co-Inventor Count = 4.9

ph-index = 4

Forward Citations = 83(Granted Patents)

Company Filing History:

Telomerase Activation Sciences, Inc.

Years Active: 2008-2019

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10494398 - Phosphorodiamidate backbone linkage for oligonucleotides (2019-12-03),

2. 9913851 - Compositions and methods for increasing telomerase activity (2018-03-13),

3. 9708360 - Phosphorodiamidate backbone linkage for oligonucleotides (2017-07-18),

4. 9403866 - Compositions and methods for increasing telomerase activity (2016-08-02),

5. 8557765 - Spatially-defined macrocycles incorporating peptide bond surrogates (2013-10-15),

6. 8481721 - Compositions and methods for increasing telomerase activity (2013-07-09),

7. 8022252 - Spatially-defined macrocyclic compounds useful for drug discovery (2011-09-20),

8. RE42013 - Macrocyclic modulators of the ghrelin receptor (2010-12-27),

9. 7550431 - Spatially-defined macrocycles incorporating peptide bond surrogates (2009-06-23),

10. 7476653 - Macrocyclic modulators of the ghrelin receptor (2009-01-13),

11. 7452862 - Conformationally-controlled biologically active macrocyclic small molecules as motilin antagonists or ghrelin agonists (2008-11-18),

Title: Mahesh Ramaseshan: Innovator in Oligonucleotide Technology

Introduction

Mahesh Ramaseshan is a prominent inventor based in Sunnyvale, CA, known for his significant contributions to the field of oligonucleotide technology. With a total of 11 patents to his name, he has made remarkable advancements that have implications in gene expression and cellular therapies.

Latest Patents

One of his latest patents is focused on a phosphorodiamidate backbone linkage for oligonucleotides. This invention relates to antisense oligonucleotides that comprise at least one N3'→P5' phosphorodiamidate linkage (NPN) in the backbone. This technology is useful for modulating gene expression involved in the pathogenesis of diseases. Additionally, he has developed compounds that serve as building blocks for these antisense oligonucleotides, along with methods for preparing these building block compounds that include NPN linkages. Another significant patent involves methods and compositions for increasing telomerase activity in cells. These compositions include pharmaceutical formulations that are beneficial for treating diseases that can be addressed by enhancing telomerase activity in cells or tissues of patients. They are also useful for improving the replicative capacity of cells in culture, particularly in ex vivo cell therapy, and for promoting the proliferation of stem and progenitor cells.

Career Highlights

Throughout his career, Mahesh has worked with notable companies such as Tranzyme Pharma Inc. and Telomerase Activation Sciences, Inc. His work in these organizations has contributed to the development of innovative solutions in the biotechnology sector.

Collaborations

He has collaborated with esteemed colleagues, including Hamid R. Hoveyda and Mark L. Peterson, which has further enriched his research and development efforts.

Conclusion

Mahesh Ramaseshan's innovative work in oligonucleotide technology and telomerase activity has positioned him as a key figure in the biotechnology field. His patents reflect a commitment to advancing medical science and improving therapeutic options for various diseases.

Profile summary based on public USPTO records.